TomoTherapy Incorporated announced that Centre Oscar Lambret in France has begun treating cancer patients using the TomoTherapy Hi•Art treatment system. The system is a unique, CT platform-based radiotherapy solution for improved cancer care. This is the first of two Hi•Art treatment systems that Centre Oscar Lambret has ordered. The second system will be installed later in 2009. The decision by Centre Oscar Lambret to adopt TomoTherapy’s innovative technology follows calls for research proposals launched by the National Cancer Institute (INCA) in July 2005 to promote implementation of image-guided radiotherapy technology that was not previously available in France. To date, six centers in France have adopted TomoTherapy’s advanced cancer treatment solution, including: Institut Curie in Paris; Institut Bergonié in Bordeaux; Centre Paul Strauss in Strasbourg; Centre René Gauducheau in Saint Herblain; and Institut Claudius Regaud in Toulouse. “We are extremely pleased to announce that another well-respected institution in France, Centre Oscar Lambret in Lille, has chosen to invest in the TomoTherapy platform,” said Jef Van Dam, general manager of TomoTherapy EMEA. “We are privileged to be working with the Centre, and proud of TomoTherapy’s growing presence within France’s prestigious radiation oncology community.” Added Eric Lartigau, M.D., Ph.D., professor of Radiation Oncology at the University of Lille and chairman of the Radiation Oncology Department, director of research and co-operations at the Centre Oscar Lambret: “The choice for TomoTherapy was guided by the need to offer IMRT (intensity-modulated radiation therapy) treatment to our patients. Approximately 3,000 treatments are provided each year, with a high incidence of head and neck and pelvic or cervix tumors, so the choice was obvious. Furthermore, the IMRT delivered by TomoTherapy was the best option for us in order to implement rapidly a modern and very efficient technique. The need to distribute very accurate dose and reduce normal tissues morbidity has been a key criteria in our choice.” “The strong interest that we see for TomoTherapy equipment in France is related to the better treatment quality and increased clinical confidence that the system’s design makes possible via daily 3D image guidance and unique dose modulation capabilities,” said Patrice Lompech, sales director for TomoTherapy in France and Luxembourg. “Medical professionals are expecting that this IMRT treatment technique will be reimbursed so that more patients in France can benefit from this advanced approach.”